Global Androgenetic Alopecia Market Size To Exceed USD 7.02 Billion by 2035| CAGR of 8.24%: Industry Analysis Report

• As per Spherical Insights & Consulting, The Global Androgenetic Alopecia Market Size is Expected to Grow from USD 3.17 Billion in 2024 to USD 7.02 Billion by 2035, at a CAGR of 8.24% during the forecast period 2025-2035, owing to the launch of new therapies in the market and the rise in the number of cases.
• The leading Androgenetic Alopecia Market Companies such as Sun Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Cipla, Inc., Merck & Co., Inc., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma, Lexington Intl., LLC, Freedom Laser Therapy, Inc. (iRESTORE Hair Growth System), Curallux, LLC, Apira Science, Inc. (iGROW Laser), and Theradome Inc., Others.

Androgenetic Alopecia Treatment Market: Understanding and Treatment Algorithm:

Androgenetic alopecia, commonly known as male or female pattern baldness, is a hereditary form of hair loss. It is caused by a combination of genetic factors and the hormone dihydrotestosterone (DHT), which shortens the hair growth cycle and shrinks hair follicles. This leads to thinning hair and gradual hair loss, typically starting at the temples and crown in men, and diffuse thinning over the scalp in women. It is the most common type of hair loss worldwide and usually progresses with age. Treatment options include topical minoxidil, oral finasteride, and hair transplant surgery.

 

Androgenetic Alopecia Diagnosis:

Androgenetic alopecia is diagnosed through a detailed medical history and physical examination of the scalp. Dermatologists assess the pattern and extent of hair loss, often using tools like dermoscopy to examine hair follicles. In some cases, blood tests or scalp biopsies are performed to rule out other causes of hair loss before confirming androgenetic alopecia.

 

Androgenetic Alopecia Treatment

Treatment for androgenetic alopecia includes topical minoxidil and oral finasteride, which slow hair loss and promote regrowth by targeting hormone effects and stimulating follicles. Low-level laser therapy and platelet-rich plasma (PRP) injections may also help. In advanced cases, hair transplant surgery is an option. Early treatment improves outcomes and helps maintain existing hair.

 

Androgenetic Alopecia Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Incident Population of Androgenetic Alopecia, Gender-specific Diagnosed Incidence of Androgenetic Alopecia, Type-specific Diagnosed Incidence of Androgenetic Alopecia, Age-specific Diagnosed Incidence of Androgenetic Alopecia, Diagnosed Incident Population based on Primary Site of Androgenetic Alopecia, and Diagnosed Incident Population based on Histologic Classification of Androgenetic Alopecia Tumour in the global market covering North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa from 2024 to 2035.

 

Principal Insights

This section offers a global overview of Androgenetic Alopecia epidemiology in major markets worldwide.

 

Country Wise- Androgenetic Alopecia Multiforme Epidemiology

• The epidemiology segment provides Androgenetic Alopecia prevalence data and findings across key regions worldwide, including North America, Europe (Germany, France, Italy, Spain, and the United Kingdom), Asia-Pacific (including Japan), Latin America, the Middle East, and Africa.

 

Androgenetic Alopecia Recent Developments:

• In January 2025, Eirion Therapeutics announced the successful results of its first-in-man clinical trial for ET-02, a topical treatment for androgenic alopecia. The 5% ET-02 formulation demonstrated a six-fold increase in non-vellus hair count compared to placebo after four weeks, outperforming minoxidil in a separate study. ET-02 was well-tolerated with no significant side effects. A Phase 2 trial is planned for 2025 to further evaluate its safety and efficacy.

 

Androgenetic Alopecia Marketed Drugs:

• Minoxidil: Johnson & Johnson

Minoxidil is a topical vasodilator that stimulates hair follicle activity and prolongs the anagen (growth) phase of hair. It is FDA-approved for both male and female pattern hair loss and is available over the counter in various strengths. Regular application is required for visible results.

 

• Finasteride (Propecia): Pfizer

Finasteride is an oral 5-alpha-reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT), a hormone linked to hair follicle miniaturization. It is FDA-approved for male androgenetic alopecia and prescribed to slow hair loss and promote regrowth.

 

• Dutasteride: GlaxoSmithKline (off-label use)

Dutasteride is a dual 5-alpha-reductase inhibitor that reduces DHT levels more effectively than finasteride. Though primarily approved for benign prostatic hyperplasia, it is increasingly used off-label for male pattern hair loss with promising results.

 

Androgenetic Alopecia Emerging therapies

• Pyrilutamide (KX-826): Pyrilutamide is a topical nonsteroidal antiandrogen in late-stage clinical trials for androgenetic alopecia. It blocks androgen receptors in hair follicles, reducing hair loss and promoting regrowth without the hormonal side effects of oral treatments.
• ET-02: It is a topical treatment that restores normal function to hair follicle stem cells. It demonstrated significant hair regrowth in early clinical trials by targeting age-related stem cell defects responsible for hair loss.
• PP405: It is a novel topical small molecule that reactivates dormant hair follicle stem cells. It is currently in Phase 2 clinical trials aimed at promoting hair regrowth in both men and women with androgenetic alopecia.
• Clascoterone: It is a topical androgen receptor inhibitor in Phase 3 trials for androgenetic alopecia. It blocks androgen effects locally in the scalp to reduce hair follicle miniaturization with minimal systemic absorption.

 

Androgenetic Alopecia Market Outlook

• The androgenetic alopecia market includes products and treatments for genetic hair loss, such as pharmaceuticals, topicals, and devices. It focuses on slowing hair loss and promoting regrowth. Growth is driven by rising awareness, technological advances, and increasing demand for effective hair restoration solutions globally.
• The increasing prevalence of hair loss, rising awareness of treatment options, and growing disposable incomes are fueling market growth. Advances in pharmaceutical and cosmetic technologies, an expanding aging population, and the introduction of innovative, effective therapies have also boosted patient demand worldwide.
• Expanding markets in developing regions, ongoing research in novel therapies, and the rising popularity of personalized hair loss treatments present significant opportunities. Additionally, growing acceptance of non-invasive and natural products, along with increasing investments in digital healthcare and teledermatology, can further drive market growth.
• High treatment costs, side effects, limited awareness in some regions, and fierce competition pose significant challenges in the androgenetic alopecia market.
• The androgenetic alopecia market is forecasted to grow steadily, driven by innovation, rising awareness, and expanding access, despite challenges like cost and side effects.

 

Androgenetic Alopecia Market Segmentation

By Gender:

• Male
• Female

The Male gender segment dominates the androgenetic alopecia market because androgenetic alopecia is more prevalent and visibly progressive in men due to higher sensitivity to dihydrotestosterone (DHT). Men typically experience earlier onset and more noticeable hair loss patterns, leading to higher treatment demand and product adoption.

 

By Treatment

• Pharmaceuticals
• Devices

The Pharmaceuticals segment dominates the androgenetic alopecia market due to the widespread use of clinically proven treatments like minoxidil and finasteride. These drugs offer accessible, effective, and regulated options for hair loss management, leading to strong physician recommendations, higher consumer trust, and consistent global demand.

 

Regional Segment Analysis of the Androgenetic Alopecia Market

North America dominates the androgenetic alopecia market due to its advanced healthcare infrastructure, high awareness of hair loss treatments, and strong consumer spending on aesthetic and wellness products. The presence of key pharmaceutical players, widespread availability of FDA-approved therapies, and active clinical research further strengthen the region’s market leadership.

 

The Asia Pacific region is the fastest-growing market for androgenetic alopecia, driven by rising awareness of hair loss treatments and increasing cosmetic concerns, particularly among younger individuals. Economic growth across countries like China, India, and South Korea has boosted disposable incomes, enabling greater access to advanced therapies and aesthetic care. The region also benefits from a large and aging population, contributing to a growing patient base.

 

Androgenetic Alopecia Market Key Companies

• Sun Pharmaceutical Industries Ltd.
• Johnson & Johnson Services, Inc.
• Cipla, Inc.
• Merck & Co., Inc.
• Dr. Reddy’s Laboratories Ltd.
• Aurobindo Pharma
• Lexington Intl., LLC
• Freedom Laser Therapy, Inc.
• Curallux, LLC
• Apira Science, Inc.
• Theradome Inc.
• Others

 

Androgenetic Alopecia Therapeutics Market Report Scope

• The Androgenetic Alopecia therapeutics market report provides a detailed overview, covering its causes, symptoms, disease progression, and existing treatment options.
• Detailed insights into Androgenetic Alopecia’s epidemiology and therapeutic approaches are included.
• Additionally, a comprehensive review of existing and emerging Androgenetic Alopecia therapies is provided, including an evaluation of new treatments expected to influence the current Androgenetic Alopecia treatment market landscape.
• The report includes a detailed review of the Androgenetic Alopecia therapeutics market, both historical and forecasted, highlighting the global drug reach.
• The Patient-Based Androgenetic Alopecia Market Forecasting report offers valuable insights into trends shaping the global Androgenetic Alopecia market, helping to develop effective business strategies.

 

Androgenetic Alopecia Treatment Market Report Insights

• Forecasting Market Trends Based on Patient Data and Disease Rates
• Androgenetic Alopecia Therapeutic Approaches in Androgenetic Alopecia
• Review Of Drugs in Development for Androgenetic Alopecia
• Market, Growth, and Trends in Androgenetic Alopecia
• Market Opportunities in Androgenetic Alopecia Treatment
• Effects Of Future Therapies on Androgenetic Alopecia Treatment.

 

Androgenetic Alopecia Treatment Market Report Key Strengths

• 15 Years Androgenetic Alopecia Market Forecast
• Global Coverage
• Androgenetic Alopecia Epidemiology Segmentation
• Key Cross Competition

 

Androgenetic Alopecia Treatment Market Report Assessment

• Present Practices in the Androgenetic Alopecia Treatment Market
• Review of Investigational Androgenetic Alopecia Drugs
• Attractiveness of the Androgenetic Alopecia Drug Market
• Androgenetic Alopecia Market Drivers
• Androgenetic Alopecia Market Barriers
• SWOT

 

Market Segment

This study forecasts revenue at the global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the androgenetic alopecia market based on the below-mentioned segments:

 

Global Androgenetic Alopecia Market, By Gender

• Male
• Female

 

Global Androgenetic Alopecia Market, By Treatment

• Pharmaceuticals
• Devices

 

Global Androgenetic Alopecia Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa